These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30536988)

  • 21. Low plasma serotonin linked to higher nigral iron in Parkinson's disease.
    Jellen LC; Lewis MM; Du G; Wang X; Galvis MLE; Krzyzanowski S; Capan CD; Snyder AM; Connor JR; Kong L; Mailman RB; Brundin P; Brundin L; Huang X
    Sci Rep; 2021 Dec; 11(1):24384. PubMed ID: 34934078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.
    Kim TH; Lee JH
    PLoS One; 2014; 9(11):e112512. PubMed ID: 25386854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.
    Barbosa JH; Santos AC; Tumas V; Liu M; Zheng W; Haacke EM; Salmon CE
    Magn Reson Imaging; 2015 Jun; 33(5):559-65. PubMed ID: 25721997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.
    He N; Huang P; Ling H; Langley J; Liu C; Ding B; Huang J; Xu H; Zhang Y; Zhang Z; Hu X; Chen S; Yan F
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 27192177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.
    Guan X; Xu X; Zhang M
    Neurosci Bull; 2017 Oct; 33(5):561-567. PubMed ID: 28516282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
    Du G; Wang E; Sica C; Chen H; De Jesus S; Lewis MM; Kong L; Connor J; Mailman RB; Huang X
    Mov Disord; 2022 Aug; 37(8):1654-1662. PubMed ID: 35614551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
    Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
    J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease.
    Khedher L; Bonny JM; Marques A; Durand E; Pereira B; Chupin M; Vidal T; Chassain C; Defebvre L; Carriere N; Fraix V; Moro E; Thobois S; Metereau E; Mangone G; Vidailhet M; Corvol JC; Lehéricy S; Menjot de Champfleur N; Geny C; Spampinato U; Meissner W; Frismand S; Schmitt E; Doé de Maindreville A; Portefaix C; Remy P; Fénelon G; Luc Houeto J; Colin O; Rascol O; Peran P; Durif F;
    Neuroimage Clin; 2022; 36():103231. PubMed ID: 36279753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra.
    Lee H; Cho H; Lee MJ; Kim TH; Roh J; Lee JH
    Radiology; 2021 Dec; 301(3):682-691. PubMed ID: 34609198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease.
    Bunzeck N; Singh-Curry V; Eckart C; Weiskopf N; Perry RJ; Bain PG; Düzel E; Husain M
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1136-42. PubMed ID: 24025315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
    Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
    BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substantia nigra hyperechogenicity in essential tremor and Parkinson's disease: a longitudinal study.
    Cardaioli G; Ripandelli F; Paolini Paoletti F; Nigro P; Simoni S; Brahimi E; Romoli M; Filidei M; Eusebi P; Calabresi P; Tambasco N
    Eur J Neurol; 2019 Nov; 26(11):1370-1376. PubMed ID: 31094036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Xing Y; Sapuan AH; Martín-Bastida A; Naidu S; Tench C; Evans J; Sare G; Schwarz ST; Al-Bachari S; Parkes LM; Kanavou S; Raw J; Silverdale M; Bajaj N; Pavese N; Burn D; Piccini P; Grosset DG; Auer DP
    Mov Disord; 2022 May; 37(5):1028-1039. PubMed ID: 35165920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
    Heilman PL; Wang EW; Lewis MM; Krzyzanowski S; Capan CD; Burmeister AR; Du G; Escobar Galvis ML; Brundin P; Huang X; Brundin L
    Mov Disord; 2020 Nov; 35(11):2028-2037. PubMed ID: 32710594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging.
    Wieler M; Gee M; Camicioli R; Martin WR
    J Neurol Sci; 2016 Feb; 361():87-91. PubMed ID: 26810522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.